Efficacy and Safety of Intraoperative Radiotherapy Combined With Serplulimab Plus Chemotherapy Versus Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Gastric or Gastroesophageal Junction Adenocarcinoma

Study acronym: NICT-IORT
StatusNot Yet Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This study evaluates the clinical efficacy and safety benefits of neoadjuvant intraoperative radiotherapy combined with immunotherapy and chemotherapy by comparing intraoperative radiotherapy plus serplulimab plus chemotherapy versus serplulimab plus chemotherapy as neoadjuvant therapy in patients with surgically resectable locally advanced gastric and gastroesophageal junction adenocarcinoma.
Trial Details
NCT Number NCT07870798
Lead Sponsor The First Affiliated Hospital with Nanjing Medical University
Conditions
(from sponsor)		 Gastric or Gastroesophageal Junction Adenocarcinoma
Enrollment 68 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov